Fresenius Medical Care Corporation (NYSE:FMS) has been assigned an average rating of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $44.00.
Several equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Fresenius Medical Care Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Royal Bank Of Canada restated a “hold” rating and set a $44.00 target price on shares of Fresenius Medical Care Corporation in a report on Wednesday, September 13th. BidaskClub lowered shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Finally, DZ Bank AG restated a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Monday, August 7th.
Fresenius Medical Care Corporation (NYSE:FMS) traded up $0.48 during trading hours on Wednesday, hitting $48.32. 737,551 shares of the company traded hands, compared to its average volume of 287,415. The firm has a market cap of $29.74 billion, a price-to-earnings ratio of 21.94, a price-to-earnings-growth ratio of 2.10 and a beta of 0.45. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.27 and a quick ratio of 1.03. Fresenius Medical Care Corporation has a 1-year low of $38.05 and a 1-year high of $50.22.
Fresenius Medical Care Corporation (NYSE:FMS) last posted its earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by ($0.05). The business had revenue of $4.47 billion for the quarter, compared to analyst estimates of $5.20 billion. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The business’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.96 EPS. equities research analysts forecast that Fresenius Medical Care Corporation will post 2.37 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Fresenius Medical Care Corporation (FMS) Receives $44.00 Average Price Target from Brokerages” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://ledgergazette.com/2017/11/13/fresenius-medical-care-corporation-fms-receives-44-00-average-price-target-from-brokerages.html.
Institutional investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. increased its stake in Fresenius Medical Care Corporation by 3.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after buying an additional 81 shares during the period. Pacer Advisors Inc. purchased a new stake in Fresenius Medical Care Corporation during the 2nd quarter worth $179,000. FFT Wealth Management LLC purchased a new stake in Fresenius Medical Care Corporation during the 2nd quarter worth $201,000. HPM Partners LLC purchased a new stake in Fresenius Medical Care Corporation during the 2nd quarter worth $221,000. Finally, YorkBridge Wealth Partners LLC increased its stake in Fresenius Medical Care Corporation by 19.4% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after buying an additional 749 shares during the period. 2.61% of the stock is currently owned by hedge funds and other institutional investors.
Fresenius Medical Care Corporation Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.